{"id":"locally-directed-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions"},{"rate":null,"effect":"Tumor-related pain or inflammation"},{"rate":null,"effect":"Systemic adverse events (variable by agent)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This approach involves administering drugs, biologics, or other therapeutic modalities directly into or adjacent to tumors, allowing high local concentrations at the disease site while reducing systemic toxicity. The strategy can encompass intratumoral injection, regional perfusion, or other localized delivery methods designed to enhance efficacy and tolerability compared to systemic administration.","oneSentence":"Locally directed therapy delivers therapeutic agents directly to tumor sites to maximize local drug concentration while minimizing systemic exposure.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:20.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors amenable to local administration (specific indications vary by formulation and trial design)"}]},"trialDetails":[{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT07067138","phase":"NA","title":"A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-02-23","conditions":"Breast Cancer, Breast Carcinoma, Cancer of the Breast","enrollment":175},{"nctId":"NCT04143711","phase":"PHASE1, PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":"Solid Tumor, Adult","enrollment":270},{"nctId":"NCT05115760","phase":"NA","title":"Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2022-04-05","conditions":"Locally Advanced Head and Neck Carcinoma","enrollment":57},{"nctId":"NCT06414590","phase":"PHASE2","title":"Neoadjuvant Tebentafusp for Uveal Melanoma","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-09-05","conditions":"Locally Advanced Unresectable Uveal Melanoma","enrollment":19},{"nctId":"NCT04221945","phase":"PHASE3","title":"Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-12","conditions":"Uterine Cervical Neoplasms","enrollment":1060},{"nctId":"NCT07400809","phase":"","title":"Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.","status":"RECRUITING","sponsor":"Tata Memorial Hospital","startDate":"2023-08-23","conditions":"Chemotherapy, Treatment Compliance, Radiotherapy","enrollment":350},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT07228637","phase":"NA","title":"Pursuing Exploration Into the Supportive Care Needs and Intervention Preferences of Survivors of Testicular Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Indiana University","startDate":"2025-08-18","conditions":"Testicular Cancer","enrollment":70},{"nctId":"NCT05827614","phase":"PHASE1","title":"Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boundless Bio, Inc.","startDate":"2023-03-24","conditions":"Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma","enrollment":85},{"nctId":"NCT05529862","phase":"NA","title":"Trans-RosaLEE Study: a Biomarker-directed, Translational Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Paoli-Calmettes","startDate":"2023-06-20","conditions":"Advanced or Metastatic Breast Cancer (BC)","enrollment":115},{"nctId":"NCT07309952","phase":"PHASE2","title":"Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Yang Hong","startDate":"2025-12-31","conditions":"Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer","enrollment":28},{"nctId":"NCT07048457","phase":"PHASE2","title":"Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-11-26","conditions":"Locally Advanced Urothelial Carcinoma, Oligo-metastaic Urothelial Carcinoma","enrollment":32},{"nctId":"NCT07222657","phase":"PHASE2","title":"Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-11","conditions":"Esophageal Adenocarcinoma, Esophageal Cancer","enrollment":40},{"nctId":"NCT04787744","phase":"PHASE2, PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":"Prostate Cancer, Oligometastasis, Oligorecurrence","enrollment":464},{"nctId":"NCT05143229","phase":"PHASE1","title":"Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-03-28","conditions":"Breast Cancer","enrollment":18},{"nctId":"NCT04227028","phase":"PHASE1","title":"Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-03-09","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma","enrollment":5},{"nctId":"NCT05107674","phase":"PHASE1","title":"A Study of NX-1607 in Adults With Advanced Malignancies","status":"RECRUITING","sponsor":"Nurix Therapeutics, Inc.","startDate":"2021-09-29","conditions":"Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer","enrollment":345},{"nctId":"NCT05862363","phase":"NA","title":"The Maternal EED Study","status":"RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2023-01-02","conditions":"Environmental Enteric Dysfunction (EED), Malnutrition, Women of Reproductive Age","enrollment":180},{"nctId":"NCT04566614","phase":"","title":"Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies","status":"COMPLETED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2020-06-18","conditions":"Neoplasm, Colorectal, Neoplasm of Lung, Neoplasm, Bladder","enrollment":128},{"nctId":"NCT04383210","phase":"PHASE2","title":"Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors","status":"TERMINATED","sponsor":"Elevation Oncology","startDate":"2020-09-29","conditions":"Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer","enrollment":54},{"nctId":"NCT06833827","phase":"NA","title":"'Thrombectomy in High-Risk Pulmonary Embolism - Device Versus Thrombolysis Netherlands': TORPEDO-NL","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-02","conditions":"Pulmonary Embolism Acute","enrollment":111},{"nctId":"NCT02401815","phase":"PHASE1, PHASE2","title":"CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Cogent Biosciences, Inc.","startDate":"2015-03-06","conditions":"Gastrointestinal Stromal Tumors","enrollment":51},{"nctId":"NCT06792149","phase":"","title":"Prediction of Drug Response in Gastric Cancer Based on 3D Bioprinting","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-10-01","conditions":"STOMACH NEOPLASM","enrollment":60},{"nctId":"NCT06786481","phase":"NA","title":"Effect of Foot Massage Performed to the Mother After Bırth on Breastfeedıng Success, Sleep Qualıty and Newborn Stress","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melek Nur KEÇELİ","startDate":"2025-01-01","conditions":"Postpartum Women","enrollment":70},{"nctId":"NCT02485834","phase":"PHASE2","title":"FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2015-11-12","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma, Gastric Cancer","enrollment":5},{"nctId":"NCT06101381","phase":"PHASE1, PHASE2","title":"CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma","status":"RECRUITING","sponsor":"University of Sao Paulo","startDate":"2024-03-21","conditions":"Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin","enrollment":81},{"nctId":"NCT05620134","phase":"PHASE1, PHASE2","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Salubris Biotherapeutics Inc","startDate":"2022-10-17","conditions":"Cancer, Tumor, Solid, Advanced Solid Tumor","enrollment":263},{"nctId":"NCT04248582","phase":"PHASE1","title":"Cryotherapy for Locally Advanced Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hunter Holmes Mcguire Veteran Affairs Medical Center","startDate":"2020-02-11","conditions":"Esophageal Cancer","enrollment":14},{"nctId":"NCT03503942","phase":"NA","title":"The Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) Program","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2017-12-30","conditions":"Pre-diabetes","enrollment":751},{"nctId":"NCT06333821","phase":"PHASE3","title":"A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2024-04-01","conditions":"Cervical Cancer","enrollment":460},{"nctId":"NCT02620280","phase":"PHASE3","title":"Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1","status":"COMPLETED","sponsor":"Fondazione Michelangelo","startDate":"2016-04","conditions":"Invasive Ductal Breast Carcinoma","enrollment":278},{"nctId":"NCT06150222","phase":"","title":"Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2023-11-30","conditions":"Cancer, Cervical, Recurrence, Metastasis","enrollment":350},{"nctId":"NCT05549414","phase":"NA","title":"Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System","status":"UNKNOWN","sponsor":"P-Cure","startDate":"2023-03-30","conditions":"Thoracic Cancer, Pancreatic Cancer Non-resectable, Brain Cancer","enrollment":100},{"nctId":"NCT03318497","phase":"PHASE2","title":"Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-12-11","conditions":"Pancreatic Adenocarcinoma","enrollment":6},{"nctId":"NCT05091528","phase":"PHASE1, PHASE2","title":"A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers","status":"TERMINATED","sponsor":"Silverback Therapeutics","startDate":"2022-02-08","conditions":"HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer","enrollment":2},{"nctId":"NCT04755907","phase":"","title":"3D Bioprinted Models for Predicting Chemotherapy Response in Colorectal Cancer With/Without Liver Metastases","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-03-01","conditions":"Colorectal Cancer, Colorectal Cancer Liver Metastasis","enrollment":120},{"nctId":"NCT04262388","phase":"PHASE2","title":"A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2021-01","conditions":"Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck","enrollment":""},{"nctId":"NCT02147990","phase":"PHASE2","title":"Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Clovis Oncology, Inc.","startDate":"2014-06-16","conditions":"Non-small Cell Lung Cancer","enrollment":318},{"nctId":"NCT01526928","phase":"PHASE1, PHASE2","title":"Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients","status":"TERMINATED","sponsor":"Clovis Oncology, Inc.","startDate":"2012-03-27","conditions":"Locally Advanced or Metastatic Non Small Cell Lung Cancer","enrollment":612},{"nctId":"NCT00079274","phase":"PHASE3","title":"Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-02","conditions":"Adenocarcinoma of the Colon, Stage III Colon Cancer","enrollment":3397},{"nctId":"NCT02322281","phase":"PHASE3","title":"TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy","status":"TERMINATED","sponsor":"Clovis Oncology, Inc.","startDate":"2015-02","conditions":"Non-small Cell Lung Cancer","enrollment":149},{"nctId":"NCT02289144","phase":"PHASE2","title":"Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2015-06","conditions":"Metastatic Anaplastic Thyroid Cancer, Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer","enrollment":""},{"nctId":"NCT03997539","phase":"PHASE2","title":"A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-08-15","conditions":"Metastatic Breast Cancer","enrollment":256},{"nctId":"NCT02186301","phase":"PHASE2, PHASE3","title":"TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy","status":"TERMINATED","sponsor":"Clovis Oncology, Inc.","startDate":"2014-11","conditions":"Non-Small Cell Lung Cancer","enrollment":100},{"nctId":"NCT02541032","phase":"PHASE3","title":"PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke","status":"UNKNOWN","sponsor":"University of South Carolina","startDate":"2015-12","conditions":"Periodontal Disease, Stroke, TIA","enrollment":400},{"nctId":"NCT00638040","phase":"","title":"The Gene Expression Studies of the Role of Tumor Microenvironments in Tumor Progression","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2009-09","conditions":"Hypoxia, Lactic Acidosis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Locally Directed Therapy","genericName":"Locally Directed Therapy","companyName":"National Cancer Institute (NCI)","companyId":"national-cancer-institute-nci","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Locally directed therapy delivers therapeutic agents directly to tumor sites to maximize local drug concentration while minimizing systemic exposure. Used for Solid tumors amenable to local administration (specific indications vary by formulation and trial design).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}